Table 1.

Patient Characteristics

		Cilengitide + Gemcitabine n = 46	Gemcitabine n = 43	Total n = 89
Age, years	Median	68	66	67
	Range	40–80	56–80	40–80
Gender (n, %)	Male	26 (57%)	18 (42%)	44 (49%)
	Female	20 (43%)	25 (58%)	45 (51%)
Stage	III	3 (7%)	4 (9%)	7 (8%)
	IV	3 (7%)	1 (2%)	4 (4%)
	IVa	3 (7%)	4 (9%)	7 (8%)
	IVb	37 (80%)	34 (79%)	71 (80%)
KP score at screening	70	3 (7%)	2 (5%)	5 (6%)
	80	19 (41%)	18 (42%)	37 (42%)
	90	18 (39%)	17 (40%)	35 (40%)
	100	6 (13%)	6 (14%)	12 (13%)

Abbreviation: KP, Karnofsky performance.